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OBJECTIVES We sought to evaluate the number and duration of device-treated and self-terminating,
nontreated episodes of atrial fibrillation (AF) after implantation of the Metrix Atrioverter.
BACKGROUND A recent study has shown that the Atrioverter can rapidly restore sinus rhythm in patients
with AF; however, the effect of the device on the clinical course of the arrhythmia in these
patients is unknown.
METHODS The Atrioverter was implanted in 51 patients with symptomatic, recurrent, drug-refractory
AF. The device was programmed to periodically monitor the cardiac rhythm. Defibrillation
of AF episodes was performed under physician observation.
RESULTS During a mean follow-up of 260 6 144 days, 1,161 episodes of AF were observed during
valid monitoring periods in 45 of 51 patients. Forty-one patients experienced 231 episodes for
which they sought defibrillation therapy. The average duration of the treated episodes during
valid monitoring periods (190 of 231 episodes in 39 of 41 patients) was significantly longer
than that of the nontreated episodes (38 6 44 vs. 10 6 8 h; p , 0.05). The time between
episodes requiring Atrioverter therapy increased, and the risk of having an episode requiring
treatment decreased. No changes were observed in the number and duration of the
short-lasting, nontreated episodes as time since implantation of the device increased.
CONCLUSIONS In patients with symptomatic, recurrent, drug-refractory AF, the frequency of long-lasting
episodes, which were treated under observation with repeated defibrillation using the
Atrioverter, decreased. The number and duration of short-lasting, nontreated episodes did
not change during the 20-month study period. The effect of ambulatory use of the device on
the recurrence of short-lasting episodes needs to be evaluated. (J Am Coll Cardiol 2000;35:
1428–33) © 2000 by the American College of Cardiology
Several nonpharmacologic options are currently available to
treat patients with atrial fibrillation (AF). Internal atrial
defibrillation using percutaneous transvenous catheter elec-
trodes has been shown to be effective and safe in converting
AF to sinus rhythm, using R-wave–synchronized, low
energy shocks (1–3). These observations resulted in the
development of an implantable atrial defibrillator (Metrix
Atrioverter, InControl, Inc., Redmond, Washington). The
Atrioverter was recently evaluated in a prospective, multi-
center study with the primary objective being the safety and
efficacy of the device (4). The Atrioverter, however, is not
only able to safely treat episodes of AF, but also to provide
information on the incidence and duration of episodes. The
aim of this study was to report on 1) the occurrences of AF
episodes, treated and nontreated by the Atrioverter; and 2)
the effect of repeated intra-atrial defibrillation on the
subsequent episodes of AF.
METHODS
Patients. From October 1995 to July 1997, the Atrioverter
was implanted in 51 patients with previous episodes of AF
that spontaneously terminated or were converted to sinus
rhythm with intervals of recurrence between one week and
three months. Previous ineffective treatment with at least
one class I or III antiarrhythmic drug was required. The
exclusion criteria of this prospective, multicenter study have
been described previously (4). Concomitant pharmacologic
treatment (e.g., anticoagulation, antiarrhythmic drugs) was
From the *Academic Hospital, Maastricht, the Netherlands; †Hoˆpital Nord,
Marseille, France; ‡InControl, Inc., Redmond, Washington; §University of Bonn,
Bonn, Germany; \University Hospital, Gent, Belgium; ¶Karolinska Hospital, Stock-
holm, Sweden; #Montreal Heart Institute, Quebec, Canada; and **St. George’s
Hospital, London, United Kingdom. ††The Metrix Investigators are listed in the
Appendix. This study was supported in part by grants from InControl, Inc.,
Redmond, Washington.
Manuscript received February 2, 1999; revised manuscript received December 3,
1999, accepted January 20, 2000.
Journal of the American College of Cardiology Vol. 35, No. 6, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00579-9
left to the preference of the physician. The Metrix model
3000 was implanted in 17 patients, and the Metrix model
3020 was implanted in the remaining 34 patients. These
two devices differ only in defibrillation waveform and output
(4).
Patients were instructed to come to the hospital for
treatment of each symptomatic episode of AF, where
defibrillation was then performed under physician observa-
tion. Data pertaining to defibrillation therapy, such as shock
characteristics and effectiveness, and clinical factors, such as
anticoagulation and antiarrhythmic medication, were re-
corded. The protocol was approved by the Ethics Commit-
tee or Institutional Review Board of each participating
center. Written, informed consent was obtained from each
patient.
Follow-up. The study ended after the last patient who
received an implant completed his three-month, postim-
plant follow-up. Postimplant clinical follow-up with device
interrogation was performed before hospital discharge and
at one-month, three-month and six-month intervals there-
after until the completion of the overall study. When the
patient sought treatment of a spontaneous episode, device
interrogation was also performed.
Definition and determination of AF episodes. Discrete
sampling of the cardiac rhythm was performed by the device
at periodic intervals. The device was programmed to per-
form an AF detection every 20 min to 1 h. Each time AF
was detected, notation of the date and the time of the
individual detection was logged to memory. Valid monitor-
ing periods were defined as the time between interrogations
of the device, where a printout of the interrogation was
made, and the device memory did not overflow owing to too
many individual AF detections during this interinterroga-
tion period (i.e., .170 individual AF detections). From the
individual detections of AF, the onset and duration of all
episodes during valid monitoring periods were recon-
structed.
Recently, Tse et al. (5) reported the long-term efficacy
results of the AF detection algorithm of the Atrioverter and
demonstrated that the algorithm had 100% specificity and
92.3% sensitivity for the detection of AF in the same patient
population. As specificity was 100%, the onset of an episode
was defined by a single AF detection. As sensitivity was
92.3%, we required at least three consecutive detections as
“not AF” before defining the end of an episode. In theory,
this method increased the sensitivity to detect the end of an
AF episode to .99%. Lastly, we excluded any patient in
whom the individual AF detection function did not meet
100% specificity and .90% sensitivity for cut-off.
Statistical analysis. Continuous variables are expressed as
the mean value 6 SD. The overall goal of this study was to
determine if the data supported the hypothesis that the
duration between treated AF episodes increases as a func-
tion of the time from implantation of the Atrioverter. For
each of the statistical analyses used in this study, the unit of
analysis is an episode rather than a patient. This is because,
in general, each patient has a multiple number of episodes,
and the actual number of episodes between patients varies.
An efficient mechanism for examining this type of data
utilizes all observations within a patient and allows interpa-
tient variability in the estimation used for statistical testing.
The methods used in this study provide for these consider-
ations.
A random effects, mixed modeling technique allows for a
variable number of repeated observations within the patients
and takes into consideration the interpatient variability. The
mixed models, random effects technique applied to these
data fits a linear function to the relation of episode length to
time since implantation, with the slope of this linear
function serving as a random effect. In essence, the slope of
a given patient’s linear relation is determined individually,
and testing of the population slope takes into account the
variability between each of the individual patient slopes for
their individual relations of episode duration and time since
implantation. Because we have multiple observations within
patients, the variability associated with the estimated slope
variable due to patient can be determined. The statistical
test to determine if the slope differs significantly from zero,
or equivalently if the mean response significantly differs over
time, therefore, allows for any interpatient variability.
For the analysis of the risk of experiencing AF episodes,
the multivariate survival analysis described by Prentice et al.
(6) was used to compare the hazard or risk of experiencing
an episode of AF as a function of time since implantation.
This technique allows for the possibility of multiple events
within patients, as well as the inclusion of the censored
period from the last AF episode to the end of patient
follow-up. For all analyses, p ,0.05 was statistically signif-
icant.
RESULTS
Patients characteristics. The clinical characteristics of the
51 patients are given in Table 1. On average, 3.9 antiar-
rhythmic drugs were tried before implantation of the device;
this includes drugs that were not tolerated and discontinued,
in addition to drugs that were only partially effective and
continued. At implantation and at the end of the study,
eight and three patients, respectively, were not treated with
antiarrhythmic drugs. During the study period, 26 (51%) of
51 patients underwent changes in their antiarrhythmic drug
regimen. At the end of the study, 32 patients were treated
with class III antiarrhythmic agents, singly or in combina-
tion with class I or rate-controlling agents, or both. Anti-
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arrhythmic treatment at the beginning and at the end of the
study period is shown in Table 2.
Before implantation, 34 patients (67%) were taking
warfarin or heparin, 9 (18%) were treated with aspirin and
8 (16%) were not receiving anticoagulation therapy. During
the course of the study, 11 patients (22%) had changes in
their anticoagulation therapy. One patient discontinued
warfarin therapy, five patients were changed from warfarin
to aspirin and five patients were started on warfarin. At the
end of the study, 13% of patients were not taking any form
of anticoagulation and an additional 23% were taking only
aspirin. No thromboembolic events occurred during the
course of the study.
Frequency and duration of AF episodes in patients with
the Atrioverter. During a follow-up of 260 6 144 days, 45
of the 51 patients had 1,230 episodes of AF recorded in the
device’s memory. Five patients had no episodes recorded
during a mean follow-up of 164 6 112 days, and one patient
was excluded owing to known AF detection problems. In 41
patients, 231 episodes were treated with the device, includ-
ing the episodes from the patient with AF detection
problems. Five patients had episodes in their device’s
memory, but received treatment for none of them.
Of the 1,230 episodes, 1,161 occurred during valid
monitoring periods (Table 3). The average recurrence rate
was 3.9 6 5.0 episodes per patient-month. Of the 231
treated episodes, 190 occurred during valid monitoring
periods in 39 of 45 patients. Six patients had no treated
episodes during valid monitoring periods. This includes the
five patients who had no treated episodes at all and one
patient who had only treated episodes that occurred during
nonvalid monitoring periods.
The number and duration of the treated and nontreated AF
episodes according to time since implantation are shown in
Table 4. The number of nontreated episodes did not change;
however, the number of treated episodes decreased. The
median duration of the treated episodes was 17.6 h, and for the
nontreated episodes, 3 h (mean 38 6 44 h vs. 10 6 18 h; p ,
0.05). In addition, 78% of the nontreated episodes were ,8 h
in length, as compared with only 28% of treated episodes.
When the distribution of the AF episodes that occurred
during valid monitoring periods was analyzed according to
the percentage of episodes treated, the following observa-
tions were made (Table 3). In 15 (33%) of the 45 patients,
Table 1. Clinical Characteristics of the 51 Study Patients
Men/women (n) 40/11
Age (yrs) 58 6 9 (31–77)




Coronary artery disease 4
Corrected congenital heart disease 2
Structural normal heart 45
LVEF (%) 58 6 11 (38–87)
LA size (cm) 4.4 6 0.8 (3.3–6.6)
Data are presented as the number of patients or the mean value 6 SD (range).
LA 5 left atrial; LVEF 5 left ventricular ejection fraction; NYHA 5 New York
Heart Association.
Table 2. Antiarrhythmic Drugs at Implantation and at the End of the Study Period
Antiarrhythmic Drug At Implantation End of Study
Single class I agent 7 8
Class I 1 rate control 3 2
Class I 1 class III 4 4
Class I 1 class III 1 rate control 0 3
Single class III agent 17 15
Combination class III agents 0 1
Class III 1 rate control 6 9
Rate control only 6 6
None 8 3
No. of antiarrhythmic drugs per patient 1.1 6 0.7 (0–3) 1.4 6 0.8 (0–3)
Data are presented as the number of patients or the mean value 6 SD (range).
Table 3. Distribution of Atrial Fibrillation Episodes in the 45
Patients According to the Percentage of Treated Episodes That














0% 6 No 37
Yes 0
1% to 10% 13 No 803
Yes 32
11% to 40% 6 No 74
Yes 27
41% to 60% 5 No 32
Yes 26
61% to 90% 7 No 24
Yes 65
91% to 100% 8 No 1
Yes 40
AF 5 atrial fibrillation.
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81% of the AF episodes were treated, and in eight of these
patients, the AF episodes were always treated. The AF
episodes occurring within a valid monitoring period from 19
patients (42%) were either not treated at all (six patients
with 37 episodes) or treated in ,10% of episodes (13
patients with 835 episodes).
Effect of Atrioverter therapy on the interval between
spontaneous episodes of AF. To evaluate the time course
of symptomatic, treated AF episode frequency, we evaluated
the duration between treated AF episodes and the risk of
having an episode as time since implantation increased. For
all these analyses, the follow-up intervals of the patients
were measured relative to the day of implantation. The
result of the first mixed models analysis is shown in Figure
1. The goal of this exploratory analysis was to examine the
mean length of time during which no AF was observed,
categorized by the number of days since implantation that
the next treated episode occurred. Only patients with two or
more spontaneous episodes for which therapy with the
Atrioverter was sought were included (n 5 33). In addition,
we only considered intervals between episodes where the
actual time was observed (i.e., we excluded from the analysis
the time from a patient’s last episode to the end of the
study). As seen in Figure 1 and the predicted line, there
appears to be a relation between the mean time between
treated episodes and time since implantation (p , 0.05).
That is, as time since implantation increases, the mean
interval between treated episodes also increases.
A graphic evaluation of the change of the risk of having
an episode requiring Atrioverter treatment is shown in
Figure 2. For this, all patients who had at least one treated
episode were included (n 5 41). For a given period since
implantation, the number of patients at risk for an episode
was determined (i.e., the number of patients actively en-
rolled in the study). The estimated risk was then calculated
as the ratio of the number of patients who had at least one
treated episode during the given period to the number of
patients at risk. As can be seen in Figure 2, the risk of
observing an episode decreased as time since implantation
increased.
Lastly, for patients who had at least one episode (n 5 41),
multivariate survival analysis was performed to examine the
Figure 1. There was an increase of the mean interval between treated spontaneous AF episodes as time since implantation of the
Atrioverter increased. Solid line 5 observed mean and standard error of the interval between treated spontaneous AF episodes; dashed
line 5 predicted mean of the interval between treated spontaneous AF episodes.
Table 4. Number and Duration of the Treated and Nontreated Atrial Fibrillation Episodes Occurring During Valid Monitoring
Periods According to Time Since Implantation
Days Since
Implantation





Mean 6 SD Median Mean 6 SD Median
0–50 213 7.5 6 15.7 2.0 93 38.9 6 42.5 22.4
51–125 261 11.6 6 20.3 3.0 48 34.0 6 44.6 15.5
126–200 224 8.2 6 19.1 2.0 33 38.5 6 47.8 13.6
.200 273 12.1 6 15.0 4.0 16 43.7 6 47.5 20.3
AF 5 atrial fibrillation; n 5 number of atrial fibrillation episodes.
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hazard or risk of experiencing an AF episode as time since
implantation increased. In general, this technique stratifies
the data by episode number, where the response is the time
between treated episodes and the number of days since
implantation is considered as a possible explanatory variable.
This analysis then tests, over strata, whether the risk of
experiencing an episode depends on the number of days
since implantation. It was shown that the hazard of expe-
riencing an episode decreased as time since implantation
increased (p , 0.05) (Table 5). On the basis of this analysis,
the risk of experiencing an episode of AF requiring defi-
brillator therapy 60 days after implantation was reduced by
73%, as compared with the risk of experiencing an episode
of AF seven days after implantation.
One other aspect that we evaluated was whether the
nontreated episodes had any impact on the prolongation of
the time between treated episodes of AF, and whether this
was caused by the patient’s reluctance to have Atrioverter
therapy. To explore this, the durations of the treated and
nontreated episodes were compared as time since implan-
tation increased. The basis for the use of this comparison is
that because the treated episodes were of longer duration, as
mentioned previously, and if potentially treatable episodes
of longer duration went untreated based on the patient’s
reluctance to have Atrioverter therapy, the mean and me-
dian duration of the nontreated episodes would increase
over time. We found that there was no increase in the
duration of the nontreated episodes over time (p . 0.05). In
fact, the number of nontreated episodes neither increased
nor diminished over time (p . 0.05).
DISCUSSION
Natural history of AF. The paroxysmal nature of AF in this
patient group is demonstrated by the presence of multiple
episodes of the arrhythmia during the 20-month follow-up
period. Although only patients with estimated arrhythmia
recurrence intervals between one week and three months were
eligible for inclusion, 5 of the 51 patients had no episodes of
AF during a mean follow-up duration of 164 6 112 days. This
may be explained by the natural history of the arrhythmia in
these patients. In addition, none of the patients who had the
device implanted at the time of the end of the study had
progressed to chronic, permanent AF.
Forty-five patients had .1,000 spontaneous AF episodes
during the follow-up period. In patients with both treated
and nontreated episodes, the treated episodes had a signif-
icantly longer duration than the nontreated ones. This is
partially due to the fact that patients had to return to the
hospital for treatment, often requiring .1 h of transporta-
tion, or that these nontreated episodes may have been
asymptomatic. When the spontaneous AF episodes were
classified according to 8-h duration, it was observed that
72% of the nontreated episodes were ,8 h, whereas 78% of
the treated episodes were .8 h in duration. These data
suggest that there are patients who have both episodes of
long duration requiring treatment as well as short or
asymptomatic episodes that are well tolerated or may go
ignored. Whether these short-lasting, nontreated episodes
affect the need for anticoagulation in the patient with an
Atrioverter remains unknown. Most patients in this study
were anticoagulated and no thromboembolic events were
seen, despite these nontreated episodes, and therefore, no
conclusions can be drawn. However, when patients are able
to treat episodes with the Atrioverter outside the hospital,
more of the shorter duration episodes may be treated and,
thus, may have an impact on the need for anticoagulation.
Reversion of long-term changes. An experimental study
in chronically instrumented goats has shown that AF
induces changes in the electrophysiologic properties of the
atria, which may lead to the development of chronic AF
(electrical remodeling) (7). This animal study suggested
interruption of the arrhythmia as soon as possible to prevent
subsequent AF episodes. The electrical atrial remodeling
completely reverted within one week after restoration of
sinus rhythm in the goats. The question that can be asked of
the data from the present study is whether the electrical
atrial remodeling has changed (reflected by a decrease in the
number of AF episodes) after repeated intra-atrial defibril-
lation of our patients with a long history of AF. If we take
both treated and nontreated AF episodes into consideration,
it seems that no reversion of the atrial electrical remodeling
has occurred at this point of follow-up. However, one must
Figure 2. Logarithmic function between the risk of a treated
spontaneous AF episode and the time since implantation of the
Atrioverter. As time since implantation increased, the risk of a
treated spontaneous AF episode decreased.
Table 5. Reduction in the Risk of a Treated Atrial Fibrillation
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also consider that a majority of these nontreated episodes
(803 episodes) were from only 13 patients, potentially
skewing the data. When only the treated episodes (190
episodes) were analyzed, the mean interval between these
AF episodes increased as time since implantation increased,
potentially denoting some form of reversion of electrical
remodeling. The unchanged frequency of nontreated epi-
sodes demonstrates that the increase in time between
treated episodes cannot be fully explained by the patient’s
reluctance to have Atrioverter therapy. The reason why the
number of the nontreated or short-lasting episodes did not
decrease over time is not yet understood. Perhaps, with the
ambulatory use of the device in either an automatic mode
(with defibrillation after a fixed time from the onset of the
episode) or a patient-activated mode, these short-lasting
episodes will also be treated and decrease over time.
Study limitations. Antiarrhythmic drugs could have
played a role in affecting the number, frequency and
duration of AF episodes after implantation of the device. As
the use of these agents was not controlled in this study, no
evaluation of their effect on possible reversibility of remod-
eling could be made from these data about the episodes.
Future studies will be needed to separate the relative
contributions of antiarrhythmic drug use and repeated
defibrillation therapy.
Symptoms were not collected from the patients during
the study. Therefore, it could not be determined whether
the nontreated episodes were asymptomatic and what the
time of onset of symptoms to device treatment was.
Conclusions. In patients with symptomatic, recurrent, drug-
refractory AF, the frequency of long-lasting episodes treated
with repeated defibrillation using the Atrioverter decreased.
The number and duration of short-lasting, nontreated episodes
did not change during the 20-month study period. Prompt
termination of all episodes of AF using out-of-hospital treat-
ment with the Atrioverter needs to be evaluated.
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